Abstract
In this issue of Anesthesia & Analgesia, Chang et al offer a systematic review comparing the effects of propofol-based total intravenous anesthesia (TIVA) with volatile anesthetics on long-term oncological outcomes. Propofol TIVA was associated with better overall survival compared to volatile anesthetics; however, there was no statistically significant difference in recurrence-free survival between groups. In a subgroup analysis, propofol TIVA was associated with better overall survival compared to desflurane but no difference was seen with sevoflurane. The reader is strongly encouraged to explore the salient details of this review to acquire an in-depth interpretation of the findings. Because the effects of anesthetic drugs are but one factor in a complex array of elements that influence cancer progression, further large-scale, randomized controlled trials are needed to further characterize the effects of anesthetic agents and cancer outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
